Evotec Stock - Analyst consensus and technical picture on Thursday
18.06.2026 - 13:10:48 | ad-hoc-news.de
Edited by ad hoc news Chart & Technicals Desk. Verified prior to publication on 06/18/2026, 11:09 UTC. Details in the imprint.
Evotec (DE0005664809) continues to attract cautious attention among German mid-cap biotech names. With no fresh corporate news, Thursday’s focus shifts to the technical setup and how analysts currently rate the recovery potential of the stock.
Background and live data on Evotec stock
All regulatory disclosures, presentations and historic quotes for Evotec stock are bundled on the issuer’s own pages and in the ad hoc news topic channel.
What the chart is signaling
On German platforms, Evotec shares most recently traded in the mid-EUR 4 range, with Tradegate quotes around EUR 4.70 and a modest intraday change, according to Tradegate data. This level leaves the stock well below its 52-week high above EUR 8 reported on specialist portals.
The 52-week span between roughly EUR 4 and EUR 8 underlines how sharply the market repriced the name over the past year. Against that backdrop, current trading levels reflect a compressed valuation compared with the company’s earlier TecDAX phase.
Analyst views and consensus snapshot
In parallel to the fragile chart, US-traded Evotec stock (ticker EVO) carries an average "Buy" consensus among a small group of analysts, according to Stock Analysis, with an average 12-month target price clearly above the latest quote. While the exact upside implied varies by source, the underlying message is cautiously constructive.
For investors, that mix of a supportive but thin analyst coverage universe and a depressed technical picture illustrates a classic mid-cap biotech pattern. The stock’s path will likely depend less on incremental sentiment shifts and more on concrete operational milestones.
The product behind the stock
Evotec’s business model is centered on discovery and development partnerships for pharmaceuticals, offering integrated drug discovery platforms and services to biotech and large pharma clients worldwide. Revenue streams typically combine research fees, milestones and potential royalties on successfully commercialized compounds.
Where the stock trades today
The shares of Evotec (DE0005664809) most recently changed hands on Tradegate around EUR 4.70 on 06/18/2026, 11:00 CET.
Key facts on Evotec stock
- Company: Evotec SE
- ISIN: DE0005664809
- WKN: 566480
- Ticker: EVT
- Venue: Tradegate
- Price (as of 06/18/2026, 11:00 CET): 4.70 EUR
- Market cap: 919,860,000 EUR (as of 06/18/2026)
- Sector / Industry: Health Care / Pharmaceuticals - Specialty and Generic
- Index membership: TecDAX, SDAX, HDAX, SDAX Kursindex
- Next earnings date: not officially scheduled
This article was AI-assisted and editorially reviewed. Price and company data without warranty; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Trading securities involves risk up to total loss of capital.
